A new analysis of a major clinical trial shows that Repatha, a cholesterol-lowering medication, reduced the risk of heart attack and stroke by 29% in people with high-risk diabetes when added to standard statin therapy. The findings, presented at the American Diabetes Association's 86th Scientific Sessions, highlight both a promising treatment option and a troubling gap between what works in clinical trials and what actually happens in real-world medical practice.

What Makes This Diabetes Population So High-Risk?

The study focused on a specific group of diabetes patients facing elevated cardiovascular danger. Researchers analyzed data from 6,002 participants with high-risk diabetes, defined as those with microvascular disease (damage to small blood vessels), current insulin use, or diabetes lasting 10 years or longer. All participants had elevated LDL cholesterol (the "bad" cholesterol that clogs arteries) and no prior history of heart attack or stroke.

People with diabetes already face double the risk of heart attack or stroke compared to those without the condition. This subgroup analysis reveals just how critical aggressive cholesterol management becomes for these vulnerable patients. The median baseline LDL cholesterol level was 122 mg/dL (considered high), and participants were already on the highest tolerated doses of statins or other standard cholesterol medications before Repatha was added.

How Much Did Repatha Lower Cholesterol and Prevent Heart Events?

When Repatha was added to existing cholesterol treatments, it achieved dramatic reductions in LDL cholesterol levels. In a lipid sub-study of 898 patients, those taking Repatha achieved a median LDL cholesterol of 45 mg/dL, compared to 106 mg/dL in the placebo group. This aggressive lowering of cholesterol translated into measurable cardiovascular protection.

The primary findings showed that Repatha reduced the risk of major cardiovascular events by 29% compared with placebo. Specifically, the drug lowered the composite risk of coronary heart disease death, heart attack, or ischemic stroke. A broader measure that included additional procedures to restore blood flow showed a 21% risk reduction. The study followed participants for a median of approximately 4.6 years, providing substantial evidence of sustained benefit.

"People with diabetes face double the risk of heart attack or stroke compared to those without the condition. These VESALIUS-CV results show that early, intensive LDL-C reduction to 45 mg/dL with Repatha is critical to help prevent life-altering cardiovascular events in those with high-risk disease," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen.

Jay Bradner, Executive Vice President of Research and Development at Amgen

Notably, the benefits held true regardless of whether patients were also taking newer diabetes medications like SGLT2 inhibitors or GLP-1 receptor agonists. Approximately one-third of participants used SGLT2 inhibitors at some point, and one-fifth used GLP-1 agonists, yet Repatha provided consistent cardiovascular protection across both groups.

Why Are Patients Abandoning Weight Loss and Diabetes Medications?

While the Repatha findings are encouraging, Amgen's presentation of real-world evidence at the conference revealed a more sobering reality. Multiple studies showed that although GLP-1 receptor agonists (the class of medications that includes popular weight loss drugs) can produce meaningful improvements in blood sugar control and weight loss, these benefits depend entirely on patients continuing to take the medication consistently.

The data painted a troubling picture of treatment persistence. Across multiple real-world studies, persistence and adherence to GLP-1 therapies remained low in routine clinical practice. Many patients discontinued treatment within the first year, potentially limiting their ability to achieve guideline-recommended blood sugar targets and weight loss goals. This gap between clinical trial results and real-world outcomes suggests that the impressive benefits seen in controlled studies may not translate to typical patients in everyday medical settings.

Steps to Improve Long-Term Treatment Success

• Sustained Treatment Use: Patients need to understand that the full benefits of GLP-1 medications and other chronic disease treatments require ongoing use, not short-term courses. Stopping medication early prevents achievement of guideline-recommended targets.
• Multiple Risk Factor Management: People with diabetes benefit from treating several interconnected problems simultaneously, including uncontrolled LDL cholesterol with medications like Repatha, blood sugar control with GLP-1 agonists or SGLT2 inhibitors, and lifestyle modifications.
• Care Strategy Innovation: Healthcare systems need new approaches and support strategies that help patients remain on therapy longer, such as simplified dosing schedules, better patient education about long-term benefits, and regular follow-up appointments to address side effects or concerns.

The research underscores an important gap in cardiometabolic care. Amgen noted that while multiple effective therapies exist for diabetes, obesity, and cardiovascular disease, the real challenge lies not in developing new drugs but in helping patients use existing treatments consistently over time.

The VESALIUS-CV trial itself was a large, rigorous Phase 3 randomized controlled trial that enrolled more than 12,000 patients with either known cardiovascular disease or high-risk diabetes. Participants were randomly assigned to receive either Repatha or placebo in addition to optimized lipid-lowering therapy. The results were published in the New England Journal of Medicine in November 2025, providing peer-reviewed validation of the findings.

For people with high-risk diabetes, the message is clear: aggressive cholesterol management with medications like Repatha, combined with consistent use of other cardiometabolic therapies, offers meaningful protection against heart attack and stroke. However, the real-world data suggests that healthcare providers and patients alike need to prioritize treatment adherence and develop better strategies to support long-term medication use. The gap between what works in clinical trials and what happens in everyday practice remains one of the most pressing challenges in modern medicine.